# AstraZeneca: Observational study completed, 1368 enrolled (COPD)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | Boosting Regional Integration for COP D Care Through Guided Implementation and Audit of Post Exacerbation Transition Bundle |
| NCT ID | NCT06646419 |
| Phase | Observational |
| Status | completed |
| Conditions | COPD |
| Target enrollment | 1368 |
| Site countries | China |
| Posted | 2024-10-17 |
| Planned start | 2024-11-13 |
| Event | Completed |
| Event date | 2026-09-21 |
| Last update posted | 2026-10-09 |

## Why this score
- Industry sponsor (buys outsourced services).
- Completed: closeout, analysis and the next study ahead.
- 1368 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT06646419). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.